Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, topical and intralesional vitamin D3 and its analogs were found to be effective and safe treatments for mild-to-moderate alopecia areata, achieving a 53.75% success rate, though intralesional vitamin D3 was less effective than other treatments like corticosteroids.

In this study, microneedling with minoxidil solution showed a significantly better response in treating male androgenetic alopecia compared to microneedling with a hair multivitamin solution.

This study found that female COVID-19 survivors were more likely than males to experience multiple long-term post-COVID symptoms, including fatigue, pain, hair loss, and mood disorders.

This review discusses the potential benefits of photobiomodulation for managing side effects of cancer therapy and provides specific guidelines for its use in supportive cancer care, without presenting new clinical results.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This review examines the use of computer vision techniques, specifically deep learning architectures and image processing algorithms, for detecting and assessing skin conditions like vitiligo and dermatitis, and highlights the need for disease-specific datasets to improve automated diagnostic tools in dermatology.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This study found that platelet-rich plasma treatment was an effective and safe option for reducing severity in patients with mild patch-type alopecia areata.

In this study, baricitinib was effective in improving hair regrowth in patients with severe alopecia areata over one year, especially when treatment began within four years of symptom onset.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

In this study, intralesional pentoxifylline was found to be an effective and well-tolerated treatment for alopecia areata, showing significant improvements in hair loss with minimal side effects and a low recurrence rate among the 50 patients tested over 12 weeks.

This pilot study found that an 8-week treatment with a hyaluronic acid and hydrogen peroxide gel improved folliculitis symptoms and patient satisfaction, supporting its potential use in dermatologic practice and future trials.

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

In this study, seven patients with refractory alopecia areata treated with concentrated growth factor and microneedling-assisted betamethasone experienced significant hair regrowth, with one achieving over 50% regrowth and six showing complete recovery, without adverse effects.

This study found significant hair growth improvement with microneedling radiofrequency treatment in most patients with patterned hair loss, with minimal short-term adverse effects.

In this study, researchers developed a computational method called iEdgePathDDA that prioritizes anticancer drug candidates by analyzing changes in gene interactions, demonstrating superior performance compared to existing methods across colorectal, breast, and lung cancer datasets.

This article reviews existing research on the treatment of alopecia areata using growth factors and microneedling, reporting that these methods show promise in promoting hair growth without major adverse effects, but emphasizes the need for additional large-scale studies to confirm their efficacy and safety.

This study evaluated the clinical outcomes of using tattoo equipment to deliver a combination of minoxidil and dutasteride directly to the scalp over three sessions for treating male androgenetic alopecia, but results are not reported in the abstract.

This study analyzed online information about PCOS and found that while the accuracy of the information was generally high, the readability was poor, suggesting a need for more accessible resources for patients.

This study outlines treatment options for alopecia, suggesting intralesional corticosteroids for localized adult cases and Janus Kinase inhibitors for severe cases, emphasizing a balance between hair regrowth rate and managing side effects.

This study reviews Korean medicine treatments for alopecia and found potential benefits, though side effects like pruritus and headache were reported; further research is needed to solidify treatment guidelines.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

In this clinical trial, 16 women with frontal fibrosing alopecia experienced significant improvements in hair density, vellus hair count, and quality of life after monthly intralesional dutasteride treatments, though larger and longer-term studies are needed to confirm these findings.

This study found that intradermal minoxidil 5% alone and with intralesional triamcinolone acetonide significantly reduced alopecia areata dermoscopic findings, while standard intralesional corticosteroids remain the main first-line treatment for patchy alopecia with less than 50% scalp involvement.

This review discusses the long-term effects of gender affirming hormone therapy and reports no new clinical findings, recommending a shared decision-making approach to balance benefits and risks for transgender individuals.

This study found no significant difference in hair cortisol concentrations, a chronic stress indicator, between sows in farrowing crates and those in loose-housing systems.